Synthesis and characterisation of thiobarbituric acid enamine derivatives, and evaluation of their α-glucosidase inhibitory and anti-glycation activity

References

• NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4*4 million participants. Lancet 2016;387:1513–30.
   PubMed Web of Science ®Google Scholar
• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271–81.
   PubMed Web of Science ®Google Scholar
• Chiarelli F, Marzio DD. Peroxisome-proliferator-activated receptor-g agonists and diabetes: current evidence and future perspectives. Vasc. Health Risk Manage 2008;4:297–304.
   PubMedGoogle Scholar
• Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998;47:345–51.
   PubMed Web of Science ®Google Scholar
• Gloster TM, Davies GJ. Glycosidase inhibition: assessing mimicry of the transition state. Org Biomol Chem 2010;8:305–20.
   PubMed Web of Science ®Google Scholar
• He Z-X, Zhou Z-W, Yang Y, et al. Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol 2015;42:125–38.
   PubMed Web of Science ®Google Scholar
• Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008;88:1254–64.
   PubMed Web of Science ®Google Scholar
• Sonama V, Kakkar R. Isatin and its derivatives: a survey of recent syntheses, reactions, and applications. Med Chem Commun 2019;10:351–36.
   Web of Science ®Google Scholar
• Chai TT, Kwek MT, Ong HC, Wong FC. Water fraction of edible medicinal fern Stenochlaena palustrisis a potenta-glucosidase inhibitor with concurrent antioxidant activity. Food Chem 2015;186:26–31.
   PubMed Web of Science ®Google Scholar
• de Melo EB, Gomes A, da S, Carvalho I. α- and β Glucosidase inhibitors: chemical structure and biological activity. Tetrahedron 2006;62:10277–302.
   Web of Science ®Google Scholar
• Ghani U. Re-exploring promising a-glucosidase inhibitors for the potential development into oral anti-diabetic drugs: finding needle in the haystack. Eur J Med Chem 2015;103:133–62.
   PubMed Web of Science ®Google Scholar
• Saeedi M, Hadjiakhondi A, Nabavi SM, Manayi A. Heterocyclic compounds: effective a-amylase and a-glucosidase inhibitors. Curr Top Med Chem 2016;17:428–40.
   Web of Science ®Google Scholar
• Min-Kyu P, Yun-Hee R, Hyo-Jung L, et al. Antiplatelet and antithrombotic activity of indole-3-carbinol in vitro and in vivo. Phytother Res 2008;22:58–64.
   PubMed Web of Science ®Google Scholar
• Penthala NR, Yerramreddy TR, Madadi NR, Crooks PA. Synthesis and in vitro evaluation of N-alkyl-3-hydroxy-3-(2-imino-3-methyl-5-oxoimidazolidin-4-yl)indolin-2-one analogs as potential anticancer agents. Bioorg Med Chem Lett 2010;20:4468–71.
   PubMed Web of Science ®Google Scholar
• Goodman LS, Gilman A. The pharmacological basis of therapeutics. New Delhi: McGraw-Hill; 1991:358–360.
   Google Scholar
• Radwan MAA, Ragab EA, Sabry NM, El-Shenawy SM. Synthesis and biological evaluation of new 3-substituted indole derivatives as potential anti-inflammatory and analgesic agents. Bioorg Med Chem 2007;15:3832–41.
   PubMed Web of Science ®Google Scholar
• Madadi NR, Penthala NR, Brents LK, et al. Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2cannabinoid receptors. Bioorg Med Chem Lett 2013;23:2019–21.
   PubMed Web of Science ®Google Scholar
• Maquoi E, Sounni NE, Devy L, et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 2004;10:4038–47.
   PubMed Web of Science ®Google Scholar
• Milanesi E, Costantini P, Gambalunga A, et al. The mitochondrial effects of small organic ligands of BCL-2 sensitization of DCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivatives. J Biol Chem 2006;28:10066–72.
   Web of Science ®Google Scholar
• Duan JJ-W, Lu ZH, Wasserman ZR, et al. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor alpha converting enzyme. Bioorg Med Chem Lett 2005;15:2970–3.
   PubMed Web of Science ®Google Scholar
• Hong TJ, Park H, Kim YJ, et al. Identification of new Hsp90 inhibitors by structure-based virtual screening. Bioorg Med Chem Lett 2009;19:4839–53.
   PubMed Web of Science ®Google Scholar
• Barakat A, Soliman SM, Al-Majid AM, et al. Synthesis and structure investigation of novel pyrimidine-2,4,6-trione derivatives of highly potential biological activity as anti-diabetic agent. J Mol Struct 2015;1098:365–76.
   Web of Science ®Google Scholar
• Badawey E, El-Ashmawey I. Nonsteroidal antiinflammatory agents-part 1: antiinflammatory, analgesic and antipyretic activity of some new 1-(pyrimidin-2-yl)-3-pyrazolin-5-ones and 2-(pyrimidin-2-yl)-l,2,4,5,6,7-hexahydro-3H-indazol-3-ones. Eur J Med Chem 1998;33:349–61.
   Web of Science ®Google Scholar
• Goodman LS, Gilman A. The pharmacological basis of therapeutics. New Delhi: McGraw-Hill; 1991.
   Google Scholar
• Andrews G. Medical pharmacology. Saint Louis: The CV Mosby Company; 1976.
   Google Scholar
• Foye WO. Principles of medicinal chemistry. London: Lea & Febiger; 1989.
   Google Scholar
• Guerin DJ, Mazeas D, Musale MS, et al. Uridine phosphorylase inhibitors: chemical modification of benzyloxybenzyl-barbituric acid and its effects on urdpase inhibition. Bioorg Med Chem Lett 1999;9:1477–80.
   PubMed Web of Science ®Google Scholar
• Rayburn ER, Ezell SJ, Zhang R. Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol 2009;1:29–43.
   PubMedGoogle Scholar
• De Belin JY, Martin MR, Fin PW, et al. Barbituric acid analogs as therapeutic agents. WO 01/93841 A2; 2001.
   Google Scholar
• Barakat A, Ali M, Al-Majid AM, Yousuf S, et al. Synthesis of thiobarbituric acid derivatives: in vitro α-glucosidase inhibition and molecular docking studies. Bioorg Chem 2017;75:99–105.
   PubMed Web of Science ®Google Scholar
• Barakat A, Islam MS, Al-Majid AM, et al. Synthesis, in vitro biological activities and in silico study of dihydropyrimidines derivatives. Bioorg Med Chem 2015;23:6740–8.
   PubMed Web of Science ®Google Scholar
• Kulinich AV, Derevyanko NA, Ishchenko AA. Synthesis and spectral properties of cyanine dyes-derivatives of 10,10-dimethyl-7,8,9. 10-tetrahydro-6H-Pyrido[1,2-a]Indolium. J Photochem Photobiol 2008;198:119–25.
   Web of Science ®Google Scholar
• Gorobets NY, Yousefi BH, Belaj F, Kappe CO. Rapid microwave-assisted solution phase synthesis of substituted 2-pyridone libraries. Tetrahedron 2004;60:8633–44.
   Web of Science ®Google Scholar
• Gong Z, Xie Z, Qiu J, Wang G. Synthesis, biological evaluation and molecular docking study of 2-substituted-4,6-diarylpyrimidines as α-glucosidase inhibitors. Molecules 2017;22:1865.
   Web of Science ®Google Scholar
• Khan KM, Khan M, Karim A, et al. Xanthine oxidase inhibition by 5-aryledene N,N’-dimethylbarbituric acid derivatives. J Chem Soc Pak 2013;35:495–8.
   Web of Science ®Google Scholar
• AlSharif AM. Synthesis of new pyrimidinone derivatives and their respective biological activity assessment. Oriental J Chem 2019;35:658–67.
   Web of Science ®Google Scholar
• Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996;17:490–519.
   Web of Science ®Google Scholar
• Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018.” 2018. 2018.
   Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput Chem 2004;25:1605–12.
   PubMed Web of Science ®Google Scholar
• Daroux M, Prevost G, Maillard-Lefebvre H, et al. Advance glycation end-products: Implications for diabetic and non-diabetic nephropathies. Diabetes Metab 2010;36:1–10.
   PubMed Web of Science ®Google Scholar
• Gutierrez R. Inhibition of advanced glycation end-product formation by Origanum majorana L. In vitro and in streptozotocin-induced diabetic rats. Evid Based Compl Alter Med 2012;2012:1–8.
   Web of Science ®Google Scholar